GlaxoSmithKline plc Cash Flow-to-Debt Ratio
GlaxoSmithKline plc cash flow-to-debt ratio. GlaxoSmithKline plc (GSKN) has a Cash Flow-to-Debt Ratio of 0.05x as of September 2025, meaning its operating cash flow of MX$2.22 Billion could theoretically repay 0% of its total liabilities (MX$45.59 Billion) in one year. Check GlaxoSmithKline plc (GSKN) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of GlaxoSmithKline plc (2013–2024)
Cash flow-to-debt ratio of GlaxoSmithKline plc from 2013 to 2024. Historical debt coverage capacity for GlaxoSmithKline plc across 12 annual periods. Check GSKN cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
GlaxoSmithKline plc Cash Flow-to-Debt Ratio by Year (2013–2024)
GlaxoSmithKline plc cash flow-to-debt ratio by year from 2013 to 2024. Year-by-year debt coverage analysis for GlaxoSmithKline plc. For the full cash flow conversion analysis, see GSKN cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (MXN) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.14x | MX$6.55 Billion | MX$46.38 Billion | ▲ +19.2% |
| 2023 | 0.12x | MX$5.48 Billion | MX$46.21 Billion | ▼ -19.9% |
| 2022 | 0.15x | MX$7.40 Billion | MX$50.05 Billion | ▲ +7.4% |
| 2021 | 0.14x | MX$7.95 Billion | MX$57.76 Billion | ▼ -2.8% |
| 2020 | 0.14x | MX$8.44 Billion | MX$59.62 Billion | ▲ +8.3% |
| 2019 | 0.13x | MX$8.02 Billion | MX$61.34 Billion | ▼ -15.5% |
| 2018 | 0.15x | MX$8.42 Billion | MX$54.39 Billion | ▲ +18.4% |
| 2017 | 0.13x | MX$6.92 Billion | MX$52.89 Billion | ▲ +8.9% |
| 2016 | 0.12x | MX$6.50 Billion | MX$54.12 Billion | ▲ +108.3% |
| 2015 | 0.06x | MX$2.57 Billion | MX$44.57 Billion | ▼ -60.2% |
| 2014 | 0.14x | MX$5.18 Billion | MX$35.72 Billion | ▼ -31.2% |
| 2013 | 0.21x | MX$7.22 Billion | MX$34.27 Billion | — |